|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GOLGA5 |
Gene summary for GOLGA5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GOLGA5 | Gene ID | 9950 |
| Gene name | golgin A5 | |
| Gene Alias | GOLIM5 | |
| Cytomap | 14q32.12 | |
| Gene Type | protein-coding | GO ID | GO:0000301 | UniProtAcc | Q8TBA6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9950 | GOLGA5 | LZE4T | Human | Esophagus | ESCC | 1.36e-06 | 3.57e-01 | 0.0811 |
| 9950 | GOLGA5 | LZE5T | Human | Esophagus | ESCC | 1.43e-02 | 3.40e-01 | 0.0514 |
| 9950 | GOLGA5 | LZE7T | Human | Esophagus | ESCC | 1.28e-02 | 2.18e-01 | 0.0667 |
| 9950 | GOLGA5 | LZE8T | Human | Esophagus | ESCC | 1.04e-03 | 2.06e-01 | 0.067 |
| 9950 | GOLGA5 | LZE20T | Human | Esophagus | ESCC | 1.08e-06 | 3.69e-01 | 0.0662 |
| 9950 | GOLGA5 | LZE22T | Human | Esophagus | ESCC | 2.55e-02 | 2.59e-01 | 0.068 |
| 9950 | GOLGA5 | LZE24T | Human | Esophagus | ESCC | 4.10e-20 | 5.33e-01 | 0.0596 |
| 9950 | GOLGA5 | LZE6T | Human | Esophagus | ESCC | 4.36e-07 | 2.62e-01 | 0.0845 |
| 9950 | GOLGA5 | P1T-E | Human | Esophagus | ESCC | 1.88e-06 | 4.61e-01 | 0.0875 |
| 9950 | GOLGA5 | P2T-E | Human | Esophagus | ESCC | 2.74e-25 | 3.50e-01 | 0.1177 |
| 9950 | GOLGA5 | P4T-E | Human | Esophagus | ESCC | 4.89e-20 | 4.48e-01 | 0.1323 |
| 9950 | GOLGA5 | P5T-E | Human | Esophagus | ESCC | 5.11e-19 | 2.99e-01 | 0.1327 |
| 9950 | GOLGA5 | P8T-E | Human | Esophagus | ESCC | 8.39e-29 | 4.76e-01 | 0.0889 |
| 9950 | GOLGA5 | P9T-E | Human | Esophagus | ESCC | 1.80e-12 | 2.53e-01 | 0.1131 |
| 9950 | GOLGA5 | P10T-E | Human | Esophagus | ESCC | 3.36e-35 | 5.93e-01 | 0.116 |
| 9950 | GOLGA5 | P11T-E | Human | Esophagus | ESCC | 1.38e-11 | 5.36e-01 | 0.1426 |
| 9950 | GOLGA5 | P12T-E | Human | Esophagus | ESCC | 1.23e-37 | 6.15e-01 | 0.1122 |
| 9950 | GOLGA5 | P15T-E | Human | Esophagus | ESCC | 5.77e-34 | 7.11e-01 | 0.1149 |
| 9950 | GOLGA5 | P16T-E | Human | Esophagus | ESCC | 1.24e-23 | 3.87e-01 | 0.1153 |
| 9950 | GOLGA5 | P17T-E | Human | Esophagus | ESCC | 8.48e-12 | 4.86e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
| GO:00070308 | Esophagus | ESCC | Golgi organization | 101/8552 | 157/18723 | 1.78e-06 | 2.10e-05 | 101 |
| GO:00068914 | Esophagus | ESCC | intra-Golgi vesicle-mediated transport | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
| GO:00070302 | Liver | HCC | Golgi organization | 99/7958 | 157/18723 | 1.54e-07 | 2.85e-06 | 99 |
| GO:0006891 | Liver | HCC | intra-Golgi vesicle-mediated transport | 22/7958 | 33/18723 | 4.38e-03 | 1.90e-02 | 22 |
| GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
| GO:00070307 | Oral cavity | OSCC | Golgi organization | 92/7305 | 157/18723 | 4.96e-07 | 7.27e-06 | 92 |
| GO:00068913 | Oral cavity | OSCC | intra-Golgi vesicle-mediated transport | 23/7305 | 33/18723 | 3.47e-04 | 2.12e-03 | 23 |
| GO:004819316 | Oral cavity | LP | Golgi vesicle transport | 141/4623 | 296/18723 | 6.11e-18 | 1.06e-15 | 141 |
| GO:000689111 | Oral cavity | LP | intra-Golgi vesicle-mediated transport | 16/4623 | 33/18723 | 2.59e-03 | 1.83e-02 | 16 |
| GO:0048193110 | Skin | cSCC | Golgi vesicle transport | 153/4864 | 296/18723 | 1.85e-21 | 3.41e-19 | 153 |
| GO:00070309 | Skin | cSCC | Golgi organization | 64/4864 | 157/18723 | 3.53e-05 | 3.83e-04 | 64 |
| GO:000689112 | Skin | cSCC | intra-Golgi vesicle-mediated transport | 18/4864 | 33/18723 | 4.45e-04 | 3.42e-03 | 18 |
| GO:004819320 | Thyroid | PTC | Golgi vesicle transport | 186/5968 | 296/18723 | 3.09e-28 | 1.22e-25 | 186 |
| GO:000703010 | Thyroid | PTC | Golgi organization | 79/5968 | 157/18723 | 1.11e-06 | 1.64e-05 | 79 |
| GO:00068916 | Thyroid | PTC | intra-Golgi vesicle-mediated transport | 20/5968 | 33/18723 | 6.26e-04 | 3.96e-03 | 20 |
| GO:0048193111 | Thyroid | ATC | Golgi vesicle transport | 189/6293 | 296/18723 | 9.58e-27 | 5.05e-24 | 189 |
| GO:000703015 | Thyroid | ATC | Golgi organization | 79/6293 | 157/18723 | 1.07e-05 | 1.05e-04 | 79 |
| GO:000689113 | Thyroid | ATC | intra-Golgi vesicle-mediated transport | 20/6293 | 33/18723 | 1.33e-03 | 6.96e-03 | 20 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GOLGA5 | SNV | Missense_Mutation | novel | c.803N>G | p.Lys268Arg | p.K268R | Q8TBA6 | protein_coding | tolerated(0.35) | benign(0.047) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| GOLGA5 | SNV | Missense_Mutation | c.604G>T | p.Val202Leu | p.V202L | Q8TBA6 | protein_coding | tolerated(0.33) | benign(0.003) | TCGA-A8-A06Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| GOLGA5 | SNV | Missense_Mutation | c.1081N>G | p.Leu361Val | p.L361V | Q8TBA6 | protein_coding | tolerated(0.09) | benign(0.442) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GOLGA5 | SNV | Missense_Mutation | c.804G>C | p.Lys268Asn | p.K268N | Q8TBA6 | protein_coding | tolerated(0.13) | benign(0.084) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GOLGA5 | insertion | Frame_Shift_Ins | novel | c.801_802insTTTTGTTCTTACT | p.Lys268PhefsTer5 | p.K268Ffs*5 | Q8TBA6 | protein_coding | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| GOLGA5 | SNV | Missense_Mutation | c.667G>A | p.Glu223Lys | p.E223K | Q8TBA6 | protein_coding | tolerated(0.58) | benign(0.014) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | |
| GOLGA5 | SNV | Missense_Mutation | c.389N>T | p.Ser130Leu | p.S130L | Q8TBA6 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GOLGA5 | SNV | Missense_Mutation | rs762876362 | c.1189N>A | p.Glu397Lys | p.E397K | Q8TBA6 | protein_coding | deleterious(0) | possibly_damaging(0.851) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| GOLGA5 | SNV | Missense_Mutation | c.982G>A | p.Glu328Lys | p.E328K | Q8TBA6 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AA-3662-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PR | |
| GOLGA5 | SNV | Missense_Mutation | c.343A>C | p.Lys115Gln | p.K115Q | Q8TBA6 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AA-3851-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |